187 related articles for article (PubMed ID: 23814017)
1. A prospective study of 67 serum immune and inflammation markers and risk of non-Hodgkin lymphoma.
Purdue MP; Hofmann JN; Kemp TJ; Chaturvedi AK; Lan Q; Park JH; Pfeiffer RM; Hildesheim A; Pinto LA; Rothman N
Blood; 2013 Aug; 122(6):951-7. PubMed ID: 23814017
[TBL] [Abstract][Full Text] [Related]
2. Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma.
Purdue MP; Lan Q; Bagni R; Hocking WG; Baris D; Reding DJ; Rothman N
Cancer Res; 2011 Jul; 71(14):4898-907. PubMed ID: 21632552
[TBL] [Abstract][Full Text] [Related]
3. Non-hodgkin lymphoma and circulating markers of inflammation and adiposity in a nested case-control study: the multiethnic cohort.
Conroy SM; Maskarinec G; Morimoto Y; Franke AA; Cooney RV; Wilkens LR; Goodman MT; Hernadez BY; Le Marchand L; Henderson BE; Kolonel LN
Cancer Epidemiol Biomarkers Prev; 2013 Mar; 22(3):337-47. PubMed ID: 23300021
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of the chemokine CXCL13, genetic variation in CXCL13 and its receptor CXCR5, and HIV-associated non-hodgkin B-cell lymphoma risk.
Hussain SK; Zhu W; Chang SC; Breen EC; Vendrame E; Magpantay L; Widney D; Conn D; Sehl M; Jacobson LP; Bream JH; Wolinsky S; Rinaldo CR; Ambinder RF; Detels R; Zhang ZF; Martínez-Maza O
Cancer Epidemiol Biomarkers Prev; 2013 Feb; 22(2):295-307. PubMed ID: 23250934
[TBL] [Abstract][Full Text] [Related]
5. Circulating inflammation markers and prospective risk for lung cancer.
Shiels MS; Pfeiffer RM; Hildesheim A; Engels EA; Kemp TJ; Park JH; Katki HA; Koshiol J; Shelton G; Caporaso NE; Pinto LA; Chaturvedi AK
J Natl Cancer Inst; 2013 Dec; 105(24):1871-80. PubMed ID: 24249745
[TBL] [Abstract][Full Text] [Related]
6. Cytokines in serum in relation to future non-Hodgkin lymphoma risk: evidence for associations by histologic subtype.
Edlefsen KL; Martínez-Maza O; Madeleine MM; Magpantay L; Mirick DK; Kopecky KJ; LaCroix AZ; De Roos AJ
Int J Cancer; 2014 Aug; 135(4):913-22. PubMed ID: 24488825
[TBL] [Abstract][Full Text] [Related]
7. Circulating Inflammation Markers, Risk of Lung Cancer, and Utility for Risk Stratification.
Shiels MS; Katki HA; Hildesheim A; Pfeiffer RM; Engels EA; Williams M; Kemp TJ; Caporaso NE; Pinto LA; Chaturvedi AK
J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26220734
[TBL] [Abstract][Full Text] [Related]
8. Pre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies.
Epstein MM; Rosner B; Breen EC; Batista JL; Giovannucci EL; Magpantay L; Aster JC; Rodig SJ; Bertrand KA; Laden F; Martínez-Maza O; Birmann BM
Haematologica; 2018 Oct; 103(10):1679-1687. PubMed ID: 29930163
[TBL] [Abstract][Full Text] [Related]
9. Soluble levels of CD27 and CD30 are associated with risk of non-Hodgkin lymphoma in three Chinese prospective cohorts.
Bassig BA; Shu XO; Koh WP; Gao YT; Purdue MP; Butler LM; Adams-Haduch J; Xiang YB; Kemp TJ; Wang R; Pinto LA; Zheng T; Ji BT; Hosgood HD; Hu W; Yang G; Zhang H; Chow WH; Kim C; Seow WJ; Zheng W; Yuan JM; Lan Q; Rothman N
Int J Cancer; 2015 Dec; 137(11):2688-95. PubMed ID: 26095604
[TBL] [Abstract][Full Text] [Related]
10. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
[TBL] [Abstract][Full Text] [Related]
11. A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma.
Purdue MP; Lan Q; Martinez-Maza O; Oken MM; Hocking W; Huang WY; Baris D; Conde B; Rothman N
Blood; 2009 Sep; 114(13):2730-2. PubMed ID: 19638620
[TBL] [Abstract][Full Text] [Related]
12. Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma.
De Roos AJ; Mirick DK; Edlefsen KL; LaCroix AZ; Kopecky KJ; Madeleine MM; Magpantay L; Martínez-Maza O
Cancer Res; 2012 Sep; 72(18):4733-43. PubMed ID: 22846913
[TBL] [Abstract][Full Text] [Related]
13. Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphoma.
Cerhan JR; Liu-Mares W; Fredericksen ZS; Novak AJ; Cunningham JM; Kay NE; Dogan A; Liebow M; Wang AH; Call TG; Habermann TM; Ansell SM; Slager SL
Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3161-9. PubMed ID: 18990758
[TBL] [Abstract][Full Text] [Related]
14. Circulating Biomarkers of Inflammation and Ovarian Cancer Risk in the Nurses' Health Studies.
Peres LC; Townsend MK; Birmann BM; Conejo-Garcia JR; Kim Y; Kubzansky LD; Magpantay LI; Martinez-Maza O; Tworoger SS
Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):710-718. PubMed ID: 33563649
[TBL] [Abstract][Full Text] [Related]
15. Association between Regular Aspirin Use and Circulating Markers of Inflammation: A Study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Lang Kuhs KA; Hildesheim A; Trabert B; Kemp TJ; Purdue MP; Wentzensen N; Katki HA; Pinto LA; Loftfield E; Safaeian M; Chaturvedi AK; Shiels MS
Cancer Epidemiol Biomarkers Prev; 2015 May; 24(5):825-32. PubMed ID: 25713025
[TBL] [Abstract][Full Text] [Related]
16. A prospective study of immune and inflammation markers and risk of lung cancer among female never smokers in Shanghai.
Shiels MS; Shu XO; Chaturvedi AK; Gao YT; Xiang YB; Cai Q; Hu W; Shelton G; Ji BT; Pinto LA; Kemp TJ; Rothman N; Zheng W; Hildesheim A; Lan Q
Carcinogenesis; 2017 Oct; 38(10):1004-1010. PubMed ID: 28981818
[TBL] [Abstract][Full Text] [Related]
17. A prospective analysis of circulating saturated and monounsaturated fatty acids and risk of non-Hodgkin lymphoma.
Chiu YH; Bertrand KA; Zhang S; Laden F; Epstein MM; Rosner BA; Chiuve S; Campos H; Giovannucci EL; Chavarro JE; Birmann BM
Int J Cancer; 2018 Oct; 143(8):1914-1922. PubMed ID: 29756258
[TBL] [Abstract][Full Text] [Related]
18. Circulating sCD27 and sCD30 in pre-diagnostic samples collected fifteen years apart and future non-Hodgkin lymphoma risk.
Purdue MP; Lan Q; Hoffman-Bolton J; Hildesheim A; Callahan CL; Strickland P; Visvanathan K; Rothman N
Int J Cancer; 2019 Apr; 144(8):1780-1785. PubMed ID: 30230539
[TBL] [Abstract][Full Text] [Related]
19. CXCL13 and CCL11 Serum Levels and Lymphoma and Disease Activity in Primary Sjögren's Syndrome.
Nocturne G; Seror R; Fogel O; Belkhir R; Boudaoud S; Saraux A; Larroche C; Le Guern V; Gottenberg JE; Mariette X
Arthritis Rheumatol; 2015 Dec; 67(12):3226-33. PubMed ID: 26359802
[TBL] [Abstract][Full Text] [Related]
20. Circulating inflammation markers and colorectal adenoma risk.
Huang WY; Berndt SI; Shiels MS; Katki HA; Chaturvedi AK; Wentzensen N; Trabert B; Kemp TJ; Pinto LA; Hildesheim A; Rothman N; Purdue MP
Carcinogenesis; 2019 Jul; 40(6):765-770. PubMed ID: 30753331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
